Regeneron Pharmaceuticals (REGN) EBIT (2009 - 2026)

Regeneron Pharmaceuticals' EBIT history runs 18 years deep, the most recent figure standing at $642.9 million for Q1 2026.

• In Q1 2026, EBIT rose 8.65% year-over-year to $642.9 million; the TTM figure through Mar 2026 stood at $3.6 billion (down 5.27% YoY), while the FY2025 annual figure was $3.6 billion, down 10.34% from the prior year.
• EBIT was $642.9 million for Q1 2026 at Regeneron Pharmaceuticals, down from $879.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $1.3 billion in Q1 2022 to a low of $591.7 million in Q1 2025.
• Historically, EBIT has averaged $999.9 million across 5 years, with a median of $1.0 billion in 2025.
• Biggest YoY gain for EBIT was 13.1% in 2022; the steepest drop was 66.84% in 2022.
• A 5-year view of EBIT shows it stood at $1.1 billion in 2022, then dropped by 15.16% to $972.9 million in 2023, then climbed by 1.78% to $990.2 million in 2024, then slipped by 11.14% to $879.9 million in 2025, then slipped by 26.93% to $642.9 million in 2026.
• The last three EBIT figures came in at $642.9 million (Q1 2026), $879.9 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.